AGP Executive Report
Last update: 5 hours agoCardiovascular Breakthrough: Evolocumab (Repatha) cut the risk of death by 20% in high-risk adults without prior heart attack or stroke in the VESALIUS-CV trial, adding mortality data to earlier event reductions. Alzheimer’s Pipeline: AbbVie’s ABBV-916 showed dose-dependent amyloid plaque reductions in early Alzheimer’s, but the program was discontinued and safety issues like ARIA appeared more often at higher exposure. Cancer Access Fix: UNC’s telehealth rapid access program for elevated PSA referrals shortened the referral-to-biopsy wait from 161 to 71 days, aiming to reduce delays in prostate cancer diagnosis. Public Health Data Tension: CDC excluded two Pennsylvania measles deaths from its national tally after a dispute over how the cases were classified, highlighting political pressure inside public health reporting. Drug Pricing Push: Trump announced new “most-favored-nation” style drug-pricing deals with nine companies to lower Medicaid prices. Substance Use Response: Massachusetts ordered emergency restrictions on kratom sales, while Montclair launched an opioid response street team funded by opioid settlement dollars. Global Health Infrastructure: South Africa’s New Development Bank signed loans for a new 488-bed Limpopo central hospital and water supply upgrades. One Health Collaboration: A regional Indo-Pacific symposium urged stronger One Health coordination to prepare for zoonotic threats as climate change accelerates risk.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
